Log in to save to my catalogue

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease...

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2829424571

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

About this item

Full title

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Publisher

England: Elsevier Ltd

Journal title

Lancet neurology, 2023-07, Vol.22 (7), p.568-577

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Multiple sclerosis typically has onset in young adults and new disease activity diminishes with age. Most clinical trials of disease-modifying therapies for multiple sclerosis have not enrolled individuals older than 55 years. Observational studies suggest that risk of return of disease activity after discontinuation of a disease-modifying therapie...

Alternative Titles

Full title

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2829424571

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2829424571

Other Identifiers

ISSN

1474-4422

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(23)00154-0

How to access this item